Cancer Summit

Targeted Therapy and Molecular Oncology Advances

Targeted therapy and molecular oncology continue to redefine cancer treatment by focusing on specific genetic mutations, signaling pathways, and molecular abnormalities that drive tumor growth and progression. Unlike conventional chemotherapy, targeted therapies are designed to selectively attack cancer cells while minimizing damage to normal tissues, resulting in improved efficacy and reduced toxicity. Advances in genomic sequencing and molecular profiling have enabled the identification of actionable mutations such as EGFR, HER2, BRAF, ALK, and KRAS, allowing clinicians to tailor treatments based on tumor biology. The development of small-molecule inhibitors, monoclonal antibodies, and antibody-drug conjugates (ADCs) has significantly expanded therapeutic options across solid tumors and hematologic malignancies. Combination strategies integrating targeted agents with immunotherapy or chemotherapy are increasingly being explored to overcome drug resistance and enhance response durability. Precision medicine initiatives and molecular tumor boards are facilitating individualized treatment planning using real-time genomic data. Furthermore, emerging research in epigenetic modulation, tumor microenvironment targeting, and pathway inhibition is opening new avenues for next-generation targeted interventions. Despite notable progress, challenges such as acquired resistance, tumor heterogeneity, high development costs, and regulatory complexities remain significant barriers. This session will highlight recent breakthroughs in molecular oncology, translational research innovations, novel drug development pipelines, and clinical trial advancements that are shaping the evolving landscape of targeted cancer therapy and improving patient-specific treatment outcomes globally.